Safety and Efficacy of Drug-Eluting Beads Trans-Arterial Chemoembolization for Hepatocellular Carcinoma in Taiwan (SERENADE-T)

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–1953.
   PubMed Web of Science ®Google Scholar
• Kuo CN, Liao YM, Kuo LN, Tsai HJ, Chang WC, Yen Y. Cancers in Taiwan: practical insight from epidemiology, treatments, biomarkers, and cost. J Formos Med Assoc. 2020;119:1731–1741.
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317–370.
   PubMed Web of Science ®Google Scholar
• Baecker A, Liu X, La Vecchia C, Zhang ZF. Worldwide incidence of hepatocellular carcinoma cases attributable to major risk factors. Eur J Cancer Prev. 2018;27:205–212.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
   PubMed Web of Science ®Google Scholar
• Nouri YM, Kim JH, Yoon HK, Ko HK, Shin JH, Gwon DI. Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma. Korean J Radiol. 2019;20:34–49.
   PubMed Web of Science ®Google Scholar
• Vogl TJ, Gruber-Rouh T. HCC: transarterial Therapies-What the Interventional Radiologist Can Offer. Dig Dis Sci. 2019;64:959–967.
   PubMed Web of Science ®Google Scholar
• Craig P, Young S, Golzarian J. Current Trends in the Treatment of Hepatocellular Carcinoma with Transarterial Embolization: variability in Technical Aspects. Cardiovasc Intervent Radiol. 2019;42:1322–1328.
   PubMed Web of Science ®Google Scholar
• Chang PY, Huang CC, Hung CH, et al. Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment. Liver Cancer. 2018;7:312–322.
   PubMed Web of Science ®Google Scholar
• Ou MC, Liu YS, Chuang MT, Lin CY, Huang LT, Lin CY. Time-to-progression following conventional compared with drug-eluting-bead transcatheter arterial chemoembolisation in patients with large hepatocellular carcinoma. Clin Radiol. 2019;74:295–300.
   PubMed Web of Science ®Google Scholar
• Liu YS, Lin CY, Chuang MT, et al. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. BMC Gastroenterol. 2018;18:124.
   PubMed Web of Science ®Google Scholar
• Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41–52.
   PubMed Web of Science ®Google Scholar
• Yang B, Liang J, Qu Z, Yang F, Liao Z, Gou H. Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: a systematic review. PLoS One. 2020;15:e0227475.
   PubMed Web of Science ®Google Scholar
• Chen P, Yuan P, Chen B, Sun J, Shen H, Qian Y. Evaluation of drug-eluting beads versus conventional transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41:75–85.
   PubMed Web of Science ®Google Scholar
• Xie ZB, Wang XB, Peng YC, et al. Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. Hepatol Res. 2015;45:190–200.
   PubMed Web of Science ®Google Scholar
• Han T, Yang X, Zhang Y, et al. The clinical safety and efficacy of conventional transcatheter arterial chemoembolization and drug-eluting beads-transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis. Biosci Trends. 2019;13:374–381.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J Hepatol. 2020;72:288–306.
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services NIH NCI. Common terminology criteria for adverse events: CTCAE v4.03.
   Google Scholar
• Young S, Craig P, Golzarian J. Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: a cross-sectional survey of techniques. Eur Radiol. 2019;29:3287–3295.
   PubMed Web of Science ®Google Scholar
• Hagan A, Phillips GJ, Macfarlane WM, Lloyd AW, Czuczman P, Lewis AL. Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies. Eur J Pharm Sci. 2017;101:22–30.
   PubMed Web of Science ®Google Scholar
• Kang YJ, Lee BC, Kim JK, et al. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2020;43:55–64.
   PubMed Web of Science ®Google Scholar
• Bolondi L, Burroughs A, Dufour JF, et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012;32:348–359.
   PubMed Web of Science ®Google Scholar
• Kudo M, Arizumi T, Ueshima K, Sakurai T, Kitano M, Nishida N. Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: proposal of Modified Bolondi’s Subclassification (Kinki Criteria). Dig Dis. 2015;33:751–758.
   PubMed Web of Science ®Google Scholar
• Hung YW, Lee IC, Chi CT, et al. Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: the Seven-Eleven Criteria. Liver Cancer. 2021;10:629–640.
   PubMed Web of Science ®Google Scholar
• Kloeckner R, Weinmann A, Prinz F, et al. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer. 2015;15:465.
   PubMed Web of Science ®Google Scholar
• Gomes AS, Monteleone PA, Sayre JW, et al. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: long-Term Survival in 313 Patients. AJR Am J Roentgenol. 2017;209:722–732.
   PubMed Web of Science ®Google Scholar
• Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol. 2012;56:1330–1335.
   PubMed Web of Science ®Google Scholar
• Aliberti C, Carandina R, Lonardi S, et al. Transarterial Chemoembolization with Small Drug-Eluting Beads in Patients with Hepatocellular Carcinoma: experience from a Cohort of 421 Patients at an Italian Center. J Vasc Interv Radiol. 2017;28:1495–1502.
   PubMed Web of Science ®Google Scholar
• Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: current state of the art. World J Gastroenterol. 2018;24:161–169.
   PubMed Web of Science ®Google Scholar
• Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64:106–116.
   PubMed Web of Science ®Google Scholar
• Torimura T, Iwamoto H. Treatment and the prognosis of hepatocellular carcinoma in Asia. Liver Int. 2021;1:548.
   Google Scholar
• Malagari K, Moschouris H, Kiakidis T, et al. Five-Years Outcome Analysis of 142 Consecutive Hepatocellular Carcinoma Patients Treated with Doxorubicin Eluting Microspheres 30-60 mum: results from a Single-Centre Prospective Phase II Trial. Cardiovasc Intervent Radiol. 2019;42:1551–1562.
   PubMed Web of Science ®Google Scholar
• Urbano J, Echevarria-Uraga JJ, Ciampi-Dopazo JJ, et al. Multicentre prospective study of drug-eluting bead chemoembolisation safety using tightly calibrated small microspheres in non-resectable hepatocellular carcinoma. Eur J Radiol. 2020;126:108966.
   PubMed Web of Science ®Google Scholar
• Demirtas CO, D’Alessio A, Rimassa L, Sharma R, Pinato DJ. ALBI grade: evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma. JHEP Rep. 2021;3:100347.
   PubMedGoogle Scholar
• Mishra G, Majeed A, Dev A, et al. Clinical utility of albumin bilirubin grade as a prognostic marker in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a systematic review and meta-analysis. J Gastrointest Cancer. 2022.
   Web of Science ®Google Scholar
• Vogl TJ, Lammer J, Lencioni R, et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol. 2011;197:W562–70.
   PubMed Web of Science ®Google Scholar
• Hagan A, Caine M, Press C, et al. Predicting pharmacokinetic behaviour of drug release from drug-eluting embolization beads using in vitro elution methods. Eur J Pharm Sci. 2019;136:104943.
   PubMed Web of Science ®Google Scholar
• Monier A, Guiu B, Duran R, et al. Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion. Eur Radiol. 2017;27:1431–1439.
   PubMed Web of Science ®Google Scholar
• Zhang ZS, Li HZ, Ma C, Xiao YD. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety. BMC Cancer. 2019;19:1162.
   PubMed Web of Science ®Google Scholar
• Karalli A, Teiler J, Haji M, et al. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting. Scand J Gastroenterol. 2019;54:905–912.
   PubMed Web of Science ®Google Scholar
• Khalaf MH, Sundaram V, AbdelRazek Mohammed MA, et al. A Predictive Model for Postembolization Syndrome after Transarterial Hepatic Chemoembolization of Hepatocellular Carcinoma. Radiology. 2019;290:254–261.
   PubMed Web of Science ®Google Scholar